Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
Guglani
S
S
Oncology Department, Cheltenham Hospital, Gloucestershire, UK. Samir.Guglani@ubht.swest.nhs.uk
Farrugia
D
D
Elsdon
M
M
Parmar
M
M
Owen
J R
JR
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001927:Brain Diseases / Q000139:chemically induced*; D001943:Breast Neoplasms / Q000188:drug therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D017093:Liver Failure; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel